Mirada Medical Supplies Deformable Fusion Technology for Varian's SmartAdapt, Presents Validati

Mirada Medical Supplies Deformable Fusion Technology for Varian's SmartAdapt, Presents Validation Study at ASTRO

ID: 70814

(firmenpresse) - OXFORD, UNITED KINGDOM -- (Marketwire) -- 09/29/11 -- Mirada Medical has integrated its multi-modal Deformable Fusion technology into Varian's SmartAdapt application and will present a study assessing the efficacy of the technology for MR to CT deformable registration at the annual meeting of the American Society for Radiation Oncology (ASTRO) in Miami, Florida.

Mirada will also be showcasing a new range of software planning tools in their exhibit (Booth #1257) that incorporate its fusion technologies to support: dose warping, dose summation, atlas based auto-contouring, deformable fusion of multi-sequence MR, PET and SPECT and single click contour warping to support adaptive re-planning.



Dr. Mark Gooding, senior scientist at Mirada, will present the study and poster presentation (#3262) at ASTRO. The study was chosen from a record breaking 2,437 abstracts submitted for review to be presented. ASTRO is the largest gathering of radiation oncology specialists in the world.

The study, titled "Assessing the quality of deformable CT-MR registration for the purpose of multi-modal radiotherapy planning," examines the performance of Mirada's multi-modal deformable registration algorithm for the fusion of head and neck, prostate and cervical diagnostic MR scans to CT planning volumes. Performance was assessed by experts in radiation oncology from four independent clinical institutions and quantitative errors were also measured using landmarks. In all cases, deformable registration significantly improved the alignment between MR and planning CT, approximately halving the registration error compared to conventional rigid alignment. The clinical experts' assessment concluded that the results required minimal intervention prior to use in multi-modal contouring.

Mirada Medical is an internationally recognised brand in advanced medical imaging. The company develops high value clinical software applications, which are used across diagnostic radiology, nuclear medicine, radiation oncology, tumor board and elsewhere.





Mirada specializes in simplifying technically complex image processing tasks, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention.

Mirada was originally spun out of the University of Oxford. The company's technologies are, to this day, developed by a team of dedicated engineers and world-renowned scientists working out of Oxford, England.

Mirada's products have been designed to ease the deployment of these powerful technologies into any hospital or imaging center workflow. Mirada's applications can be delivered using thin client or cloud based architectures, or licensed on a floating or per workstation basis. Most recently, Mirada has focused on the development of disease specific solutions for use across departments working with patients to fight cancer. In particular, Mirada's powerful image registration technologies have been tuned to the needs of radiation oncology, and quantification technologies have been redefined to optimize support for standard protocols such as RECIST and PERCIST. In addition, powerful imaging solutions have been introduced to support better collaborative working, in particular in the context of a rich web-based viewer for referring physicians and a robust solution for presentation of images at multidisciplinary meetings such as tumor board.

Mirada Medical, Mirada XD3 and Casemeeting are all trademarks of Mirada Medical Ltd.

For more information,

PDF of release:



US/Worldwide:
Robert
tel: (440) 591-8638
Insource Communications




Oxford Center for Innovation
New Road, Oxford
OX1 1BY
United Kingdom
Tel: +44(0)1865 261410


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Genedrive(TM) Passes First In-Field Tuberculosis Testing Passive Smoking and Hearing Loss: Are Links Building Between the Two?
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 29.09.2011 - 07:21 Uhr
Sprache: Deutsch
News-ID 70814
Anzahl Zeichen: 0

contact information:
Town:

OXFORD, UNITED KINGDOM



Kategorie:

Medical Devices



Diese Pressemitteilung wurde bisher 242 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Mirada Medical Supplies Deformable Fusion Technology for Varian's SmartAdapt, Presents Validation Study at ASTRO"
steht unter der journalistisch-redaktionellen Verantwortung von

Mirada Medical (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Michael Frith Joins Mirada Medical U.S. Management Team ...

DENVER, CO -- (Marketwire) -- 11/26/12 -- Mirada Medical is pleased to announce that Michael Frith has joined the company as Vice President of Sales for the U.S. This newly created position at Mirada addresses its rapidly expanding presence in the U ...

Alle Meldungen von Mirada Medical



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z